Study Finds Lenacapavir Could Be Produced for $25 Annually, Expanding Access for HIV Prevention
New research showed that lenacapavir—currently priced at more than $28,000 annually—could be mass produced for as low as $25 per person a year, potentially...
Real-World Data Show Gaps in STI Testing Adherence Among PrEP Users
People who use pre-exposure prophylaxis (PrEP) for HIV-1 prevention were tested for sexually transmitted infections (STIs) more frequently than before they began PrEP. Yet,...
Study Shows Strong Growth in Long-Acting Cabotegravir Adoption, Especially Among PrEP-Naïve Individuals
Over 3 years, adoption of long-acting cabotegravir increased, with the highest uptake observed among pre-exposure prophylaxis (PrEP)-naïve individuals who began treatment with samples. The...
Falling Short: New Research Finds Missed Opportunities in the PrEP Care Cascade
Many people who are at risk of HIV remain unprotected despite clear indications for pre-exposure prophylaxis (PrEP), revealing missed prevention opportunities, according to new...